I am/have/had
I am looking for
Advanced Filters
Found 249 clinical trials
Featured trial
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT. The hematologic recurrence rate of MRD-positive patients with adult ALL is high.
- 0 views
- 16 Mar, 2026
- 2 locations
